New hope for NF1 patients: experimental drug targets painful nerve tumors

NCT ID NCT06541847

Recruiting now Disease control Sponsor: Healx Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This phase 2 trial tests an oral drug called HLX-1502 in people aged 12 and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas—nerve tumors that can cause pain, disfigurement, or other problems. The study will enroll 25 participants and measure whether the drug can shrink tumors by at least 20% on MRI scans. It is open-label, meaning everyone knows they are getting the drug, and there is no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX-1502 (an oral drug taken three times daily)
What this could lead to: If successful, this could point toward a new treatment option to shrink or control plexiform neurofibromas in people with NF1.
What could go wrong: This is an early-phase, small study with no placebo group, so results may not be definitive. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibromatosis type 1 plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS TYPE 1

Contacts and locations

Locations

Ann & Robert H. Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States
Children's Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States
Children's Hospital Los Angeles
RECRUITING

Los Angeles, California, 90027, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Children's National Hospital
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States
Indiana University
RECRUITING

Indianapolis, Indiana, 46202, United States
Johns Hopkins Hospital
RECRUITING

Baltimore, Maryland, 21287, United States
New York University Langone Health
RECRUITING

New York, New York, 10016, United States
Stanford University
RECRUITING

Palo Alto, California, 94304, United States
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States
University of Chicago
RECRUITING

Chicago, Illinois, 60637, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.